Responses
Clinical/translational cancer immunotherapy
Original research
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Compose a Response to This Article
Other responses
No responses have been published for this article.
